Trial document



drksid header

  DRKS00003357

Trial Description

start of 1:1-Block title

Title

Dysfunctional neuronal networks in alcoholism: Utilizing translational neuroimaging to identify altered brain connectivity and treatment efficacy predictors

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

Transalc

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

http://www.transalc.eu

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

There is some evidence that the connections between different brain areas are affected by alcohol dependence. Therefore we want to investigate the differences between alchol- dependet patientes and healthy controll subjects.
With MRI (Magnet Resonance Imaging) we will make brain images using two different techniques: First Diffusions-Tensor-Imaging (DTI) to see how well and in which direction the water inclosed in the neuronal brain bundles moves. This shows whether the function of the brain bundles and the flow of information between brain areas is efficient. Second we will make a Resting-State MRI. This is to investigate the communication of brain areas without doing concentrated exercises but beeing at rest. If two areas show activity at the same time we can conclude that they have a connection.


end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Alcoholism is a common psychiatric disorder with largely unmet treatment needs. Excellent animal models for this disorder have put forward a number of promising molecular targets for medication development. Yet, clinical trials aimed at exploiting this potential often fall short of expectations. We aim to improve the predictive validity of animal tests by means of functional connectivity analysis using magnetic resonance imaging (MRI) to identify brain response patterns to pharmacotherapy that are comparable between patients and animal models of alcoholism. To this end we have formed an international consortium with highly complementary expertise in the field of alcoholism and neuroimaging research. This project will reveal alcoholism specific connectivity maps and knowledge of their modification by clinical reference compounds, i.e. acamprosate and naltrexone, in humans and animals. Based on this information we expect to predict better the effects of experimental drugs proposed for treatment of alcoholism in human patients.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003357
  •   2011/11/29
  •   [---]*
  •   yes
  •   Approved
  •   2010-348N-MA, Medizinische Ethik-Kommission II Medizinische Fakultät Mannheim der Universität Heidelberg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   F10.2 -  Mental and behavioural disorders due to use of alcohol; Dependence syndrome
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   alcohol dependent patients with anticraving medication (Naltrexone or Acamprosate)
  •   alcohol dependent patients without anticraving medication
  •   healthy controlls
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Other
  •   Non-randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Basic research/physiological study
  •   Parallel
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

To determine differences in functional connectivity between alcohol addicted patients and healthy controls using rsfMRI and DTI

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

To determine differences in functional connectivity between alcohol addicted patients treated with Naltrexone or Acamprosate vs. alcohol addicted patients without medication using rsfMRI and DTI

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
  •   Canada
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2011/12/01
  •   270
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   75   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

alcohol dependence (DSM IV; ICD 10) and
average84g of pure alcohol per day during the last 90 days

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

other Axis 1 psychiatric diagnoses than alcohol- or nicotine-dependence in the last 12 months, common exclusion criteria for MRI, positive urine drug screen, severe medical illness and history of brain injury

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Zentralinstitut für Seelische Gesundheit
    • Mr.  Prof.Dr.  Karl  Mann 
    • J 5
    • 68159  Mannheim
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Zentralinstitut für Seelische Gesundheit Klinik für Abhängiges Verhalten und Suchtmedizin
    • Mr.  Dr. med.  Derik  Hermann 
    • J5
    • 68199  Mannheim
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Zentralinstitut für Seelische Gesundheit Klinik für Abhängiges Verhalten und Suchtmedizin
    • Mr.  Dr. med.  Derik   Hermann 
    • J 5
    • 68159   Mannheim
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bundesministerium für Bildung und Forschung
    • Friedrichstraße 130 B
    • 10117   Berlin
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.